TY  - JOUR
PY  - 1999//
TI  - Fas ligand: A potential target for therapeutic induction of apoptosis and enhancing immunotherapy in cancer
JO  - Expert Opinion on Therapeutic Targets
A1  - O'Connell, J.
SP  - 601
EP  - 611
VL  - 3
IS  - 4
N2  - Fas (CD95/APO-1) is a cell surface receptor which mediates a potent apoptotic death signal upon engagement by its ligand, FasL. Since tumour cells frequently co-express Fas and FasL, the prospect of therapeutically stimulating autocrine suicide of cancer cells via the Fas pathway is tantalising. To achieve this, mechanisms of acquired resistance to Fas-mediated apoptosis, inherent in cancers, must be overcome. Indeed, expression of FasL by Fas-resistant tumours appears to enhance malignancy by triggering apoptosis of Fas-sensitive antitumour immune effector cells. Therapeutic inhibition of this "Fas counterattack" against antitumour immune responses might improve immunotherapeutic approaches. Although restoring the Fas-sensitivity of tumours and inhibiting FasL-mediated counterattack against antitumour lymphocytes have been achieved experimentally in vitro, transferring such approaches to in vivo therapy represents an enormous challenge. © 1999 Ashley Publications Ltd.<p /> <p>Language: en</p>
LA  - en
SN  - 1744-7631
UR  - http://dx.doi.org/10.1517/14728222.3.4.601
ID  - ref1
ER  -